Federal Court Dismisses Neurocrine Biosciences’ Patent Challenge Against Spruce Biosciences

Neurocrine Biosciences has experienced a legal setback after a federal judge in Delaware dismissed its lawsuit aimed at challenging a patent owned by Spruce Biosciences Inc. The patent in question covers a treatment for a hormonal disorder, and Neurocrine’s efforts to have it declared invalid have so far been unsuccessful. For more details, visit the original article on Law360.